SC
SABS icon

Sessa Capital’s SAB Biotherapeutics SABS Stock Holding History

Sessa Capital’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.42M Hold
2,198,457
– – 0.15% 30
2025
Q4 		$8.22M Hold
2,198,457
– – 0.15% 26
2025
Q3 		$4.42M Buy
2,198,457
+1,740,000
+380% +$3.93M 0.1% 25
2025
Q2 		$805K Hold
458,457
– – 0.02% 27
2025
Q1 		$624K Hold
458,457
– – 0.02% 28
2024
Q4 		$1.74M Hold
458,457
– – 0.06% 25
2024
Q3 		$1.24M Hold
458,457
– – 0.05% 28
2024
Q2 		$1.42M Hold
458,457
– – 0.04% 26
2024
Q1 		$2.08M Hold
458,457
– – 0.05% 27
2023
Q4 		$3.15M Buy
+458,457
New +$3.84M 0.11% 22

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sessa Capital's SABS Position: Q1 2026 in Review

Sessa Capital held its SAB Biotherapeutics (SABS) position steady in Q1 2026 at 2,198,457 shares worth $8.42M. The position accounts for 0.15% of the portfolio, ranked #30.

Sessa Capital first reported a position in SABS in Q4 2023 and has held it in 10 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Sessa Capital held 2,198,457 shares of SAB Biotherapeutics worth $8.42M as of Q1 2026.
  • Sessa Capital left its SAB Biotherapeutics share count unchanged in Q1 2026.
  • SAB Biotherapeutics made up 0.15% of Sessa Capital's portfolio in Q1 2026, its #30 holding.
  • Sessa Capital first reported a position in SAB Biotherapeutics in Q4 2023 and has held it in 10 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Sessa Capital's 13F filing for Q1 2026, filed 15 May 2026.